TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03385304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (1% free iodine) in purified water
Description: Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (1% free iodine) in purified water
Description: Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG) in purified water
Description: Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG) in purified water
Description: Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
Study: NCT02832375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% w/w stannous fluoride containing 1100ppm of fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Study: NCT02075528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
Study: NCT03589976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2 MG
Description: Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
Study: NCT01565668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: oral
Study: NCT03018496

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxy-Beta-Methylbutyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxy-Beta-Methylbutyrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03966924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational fractional resection (1.5mm Diameter Device)
Description: Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
Study: NCT01168908

Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil
Description: 20mg tablet three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20mg tablet three times daily
Study: NCT03216590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive draping using adhesive incise drape
Description: In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
Study: NCT03810313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study: NCT02861326

Intervention type: DEVICE
Group type: OTHER
Intervention: Gracey Curettes
Study: NCT00453531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb Ischemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Study: NCT03352193

Intervention type: DIETARY_SUPPLEMENT
Intervention: Wheat spaghetti
Description: Wheat oral immunotherapy
Study: NCT04248140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radio frequency electromagnetic field
Description: Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radio frequency electromagnetic field
Description: Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
Study: NCT04016922

Intervention type: OTHER
Intervention: Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C
Description: Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US.

Intervention type: OTHER
Intervention: Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C
Description: Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US.

Intervention type: OTHER
Intervention: Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C
Description: Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US.
Study: NCT02814786

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scanner
Description: This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scanner
Description: This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
Study: NCT03700333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 therapy
Description: accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed therapy
Description: accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
Study: NCT02372929

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Description: Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
Study: NCT03931772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Self-Hypnosis
Description: Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Self-Hypnosis
Description: Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Self-Hypnosis
Description: Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
Study: NCT03855020

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma EBV DNA
Description: Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
Study: NCT03425682

Intervention type: OTHER
Intervention: ViBone
Description: Viable Bone Allograft

Intervention type: OTHER
Intervention: ViBone
Description: Viable Bone Allograft
Study: NCT02613039

Intervention type: DRUG
Group type: OTHER
Intervention: Combined Estrogen-Progestin Oral Contraceptives
Description: All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
Study: NCT01306318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eperisone hydrochloride plus diclofenac sodium capsule
Description: Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eperisone hydrochloride tablet and diclofenac sodium tablet
Description: Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
Study: NCT03625635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized food-based intervention
Description: Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
Study: NCT00283855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Self-Management
Description: Online Self-Management
Study: NCT03937401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infusion during MRI-HIFU treatment
Study: NCT01672749

Intervention type: DEVICE
Intervention: Growth guiding construct using TROLLEY system
Description: Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)

Intervention type: DEVICE
Intervention: Spine based dual growing rod or rib based VEPTR
Description: spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
Study: NCT00288600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: Intravenous Immunoglobulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Normal saline solution 10 ml/Kg
Study: NCT01277653

Intervention type: DEVICE
Intervention: tumor maker interval shortly
Description: tumor maker interval every 3 month
Study: NCT03806699

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study: NCT02723903

Intervention type: DRUG
Group type: OTHER
Intervention: Deanxit
Description: we use Deanxit for the patient with anxiety

Intervention type: DRUG
Group type: OTHER
Intervention: Deanxit
Description: we use Deanxit for the patient with anxiety

Intervention type: DRUG
Group type: OTHER
Intervention: Prozac
Description: we use Prozac for the patient with depression

Intervention type: DRUG
Group type: OTHER
Intervention: Prozac
Description: we use Prozac for the patient with depression

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary artery disease treatment
Description: including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary artery disease treatment
Description: including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
Study: NCT02688062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen Scaffold with BMMCs transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intradural decompression and adhesiolysis
Description: Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study: NCT04183153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
Study: NCT02984163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
Study: NCT03461419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose Stroma
Description: Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV Deployment of cSVF
Description: Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
Study: NCT04370704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012.
Description: INCMGA00012 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012.
Description: INCMGA00012 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012.
Description: INCMGA00012 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012.
Description: INCMGA00012 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012.
Description: INCMGA00012 administered intravenously
Study: NCT02510105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDR4 ventilator (Intrapulmonary Percussive Ventilation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo-i

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: - Intubation
Study: NCT00152763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Description: Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Description: Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
Study: NCT02510105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation ( with an ICU conventional ventilator)
Study: NCT02155517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of propofol effect
Description: The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of propofol effect
Description: STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
Study: NCT02270359

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT
Description: Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.